Ostenfeld T, Caldwell M A, Prowse K R, Linskens M H, Jauniaux E, Svendsen C N
MRC Centre for Brain Repair, University of Cambridge, United Kingdom.
Exp Neurol. 2000 Jul;164(1):215-26. doi: 10.1006/exnr.2000.7427.
Worldwideattention is presently focused on proliferating populations of neural precursor cells as an in vitro source of tissue for neural transplantation and brain repair. However, successful neuroreconstruction is contingent upon their capacity to integrate within the host CNS and the absence of tumorigenesis. Here we show that human neural precursor cells express very low levels of telomerase at early passages (less than 20 population doublings), but that this decreases to undetectable levels at later passages. In contrast, rodent neural precursors express high levels of telomerase at both early and late passages. The human neural precursors also have telomeres (approximately 12 kbp) significantly shorter than those of their rodent counterparts (approximately 40 kbp). Human neural precursors were then expanded 100-fold prior to intrastriatal transplantation in a rodent model of Parkinson's disease. To establish the effects of implanted cell number on survival and integration, precursors were transplanted at either 200,000, 1 million, or 2 million cells per animal. Interestingly, the smaller transplants were more likely to extend neuronal fibers and less likely to provoke immune rejection than the largest transplants in this xenograft model. Cellular proliferation continued immediately post-transplantation, but by 20 weeks there were virtually no dividing cells within any of the grafts. In contrast, fiber outgrowth increased gradually over time and often occupied the entire striatum at 20 weeks postgrafting. Transient expression of tyrosine hydroxylase-positive cells within the grafts was found in some animals, but this was not sustained at 20 weeks and had no functional effects. For Parkinson's disease, the principal aim now is to induce the dopaminergic phenotype in these cells prior to transplantation. However, given the relative safety profile for these human cells and their capacity to extend fibers into the adult rodent brain, they may provide the ideal basis for the repair of other lesions of the CNS where extensive axonal outgrowth is required.
目前,全球的注意力都集中在神经前体细胞数量的激增上,将其作为神经移植和脑修复组织的体外来源。然而,成功的神经重建取决于它们在宿主中枢神经系统中整合的能力以及不发生肿瘤形成。在这里,我们表明人类神经前体细胞在早期传代(少于20次群体倍增)时端粒酶表达水平非常低,但在后期传代时降至无法检测的水平。相比之下,啮齿动物神经前体细胞在早期和后期传代时都表达高水平的端粒酶。人类神经前体细胞的端粒(约12千碱基对)也明显短于啮齿动物对应细胞的端粒(约40千碱基对)。然后,在帕金森病啮齿动物模型中,将人类神经前体细胞在纹状体内移植前扩增100倍。为了确定植入细胞数量对存活和整合的影响,每只动物分别移植200,000、100万或200万个细胞。有趣的是,在这个异种移植模型中,较小的移植体比较大的移植体更有可能延伸神经纤维,并且引发免疫排斥的可能性更小。移植后细胞增殖立即开始,但到20周时,任何移植体内几乎都没有分裂细胞。相比之下,纤维生长随时间逐渐增加,在移植后20周时通常占据整个纹状体。在一些动物的移植体内发现了酪氨酸羟化酶阳性细胞的短暂表达,但在20周时并未持续,也没有功能影响。对于帕金森病,目前的主要目标是在移植前诱导这些细胞的多巴胺能表型。然而,鉴于这些人类细胞相对安全的特性以及它们向成年啮齿动物脑内延伸纤维的能力,它们可能为中枢神经系统其他需要广泛轴突生长的损伤修复提供理想的基础。